Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Archemix and NascaCell Technologies have reported an expansion of their strategic alliance focused on the use and development of aptamers for drug discovery applications.
Subscribe to our email newsletter
Under the terms of the new agreement, NascaCell receives non-exclusive rights to uses of aptamers for target validation, mode of action studies, drug discovery, and aptamer structure-based drug design.
Future aptamer technology improvements will be cross-licensed between the companies and Archemix will have the option of contracting NascaCell to generate aptamers for its own applications.